Power EPCs, financiers top bets; pharma a four-part opportunity: Sunil Subramaniam
Sunil Subramaniam identifies EPC companies and financiers as top power sector investment opportunities, citing operating leverage benefits. He presents pharma as a four-part investment framework with recommended 60% allocation to domestic formulations and semaglutide opportunities. Market caution expected to persist until mid-February due to earnings and budget uncertainty, with second half anticipated to outperform first half.

*this image is generated using AI for illustrative purposes only.
Sunil Subramaniam, Founder and CEO of Sense and Simplicity, has identified engineering, procurement and construction (EPC) companies and financiers as the most compelling investment opportunities within India's expanding power sector. Speaking to ET Now, he emphasized that these segments offer superior operating leverage and execution-led growth potential compared to other power ecosystem participants.
Power Sector Investment Strategy
Subramaniam's investment thesis centers on the fundamental roles these companies play in India's ongoing power infrastructure development. He explained that financiers will benefit significantly as capital deployment increases across power projects, while EPC companies serve as the primary executors of these initiatives.
"Ultimately, financiers will benefit significantly as capital deployment rises, and EPC companies will be the actual executors of projects. That is where higher operating leverage comes into play," Subramaniam noted, though he refrained from commenting on specific stock preferences.
Pharmaceutical Sector: Four-Part Investment Framework
The pharmaceutical sector presents what Subramaniam describes as a "four-part puzzle" offering distinct investment opportunities across multiple segments. His framework identifies four key growth levers within the pharma space:
| Segment | Characteristics | Growth Profile |
|---|---|---|
| Semaglutide-linked opportunities | High growth potential | Elevated valuations |
| Domestic formulations | Stable performance | Consistent growth |
| Generics | Global exposure | US regulatory dependent |
| CDMO | International focus | Currency sensitive |
Subramaniam recommends a strategic allocation approach for pharma investments: "In terms of allocation, around 60% should go towards domestic pharma and the semaglutide opportunity, while the remaining 40% can be tactically split between generics and CDMO."
Market Outlook and Investment Timing
Current market weakness reflects widespread caution among institutional investors, driven by valuation concerns and uncertainty surrounding the upcoming earnings season and Union Budget. Subramaniam expects this cautious sentiment to persist through the first half of the year.
"Fund managers would rather sit on cash until there is clarity on earnings and budget announcements. Meaningful tactical allocations are likely only after mid-February," he observed.
Both foreign institutional investors (FIIs) and domestic institutional investors (DIIs) remain hesitant to deploy fresh capital, waiting for earnings visibility and clearer market direction. Subramaniam anticipates a bifurcated year with the second half performing better than the first, though he cautioned about uncertain one-year equity returns due to global trade tensions.
Sector-Specific Perspectives
China Policy and Export Potential
Regarding potential policy changes allowing Chinese firms to bid for government contracts, Subramaniam views this as a pragmatic approach balancing political and economic considerations. He believes selective Chinese participation could provide access to advanced technology and scale advantages, particularly benefiting sectors like pharmaceuticals where China remains a major active pharmaceutical ingredient supplier.
Auto and Banking Sectors
In the automotive sector, Subramaniam expects margin pressure in the near term despite robust sales volumes, as companies implement price cuts to stimulate demand. However, he believes earnings per share could remain stable due to high operating leverage.
For banking, he anticipates near-term outperformance from private sector banks and NBFCs, driven by consumer and auto-led credit growth. PSU banks, while offering valuation comfort, may see stronger momentum only in the second half, supported by potential capex revival and housing demand recovery.



























